Songjiang Ma - Oct 30, 2023 Form 3/A - Amendment Insider Report for GYRE THERAPEUTICS, INC. (GYRE)

Role
President, Director
Signature
/s/ Ruoyu Chen, as attorney-in-fact for Songjiang Ma
Stock symbol
GYRE
Transactions as of
Oct 30, 2023
Transactions value $
$0
Form type
3/A - Amendment
Date filed
11/22/2023, 07:06 PM
Date Of Original Report
Nov 1, 2023
Next filing
Nov 22, 2023

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
holding GYRE Common Stock 2.94M Oct 30, 2023 By Spouse F1, F2, F3
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 Represents the number of shares of common stock of the Issuer received by the spouse of the Reporting Person in exchange for the shares of Ratel Holdings Limited, a company incorporated in the British Virgin Islands with limited liability, held by the spouse of the Reporting Person pursuant to that certain Business Combination Agreement, dated as of December 26, 2022 and as amended on March 29, 2023 and August 30, 2023 (the "Business Combination Agreement"), by and among Catalyst Biosciences, Inc., a Delaware corporation, GNI USA, Inc., a Delaware corporation, GNI Group Ltd., a company incorporated under the laws of Japan with limited liability,
F2 [cont'd from FN 1] GNI Hong Kong Limited, a company incorporated under the laws of Hong Kong with limited liability, Shanghai Genomics, Inc., a company organized under the laws of the People's Republic of China, the Minority Holders (as defined therein) and Continent Pharmaceuticals Inc., a Cayman Islands company limited by shares. Pursuant to the terms of the Business Combination Agreement, on October 30, 2023, the Issuer acquired an indirect controlling interest in Beijing Continent Pharmaceuticals Co., Ltd, a company organized under the laws of the People's Republic of China.
F3 These shares were inadvertently omitted from the reporting person's original Form 3.